Skip to content
Biodatica
Start free

BioNTech SE

Phoenix, Arizona

OncologybispecificPhase IIIListed · BNTX

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

3d agoTrial registeredJul 16, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Apr 22, 2026

    Metastatic Castration-resistant Prostate Cancer · RECRUITING · sponsor: BioNTech SE · A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

    ClinicalTrials.gov · NCT07365995 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Feb 20, 2026

    Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection · RECRUITING · sponsor: BioNTech SE · A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

    ClinicalTrials.gov · NCT07379580 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Aug 27, 2025

    Advanced Solid Tumor · RECRUITING · sponsor: BioNTech SE · A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

    ClinicalTrials.gov · NCT07147348 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Jul 1, 2025

    Testicular Germ Cell Tumor, Extragonadal Germ Cell Tumor · WITHDRAWN · sponsor: BioNTech SE · A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm

    ClinicalTrials.gov · NCT06940804 (opens the source filing in a new tab)

  5. Trial

    PHASE1/PHASE2 registered

    May 2, 2025

    Advanced Lung Cancer · RECRUITING · sponsor: BioNTech SE · A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

    ClinicalTrials.gov · NCT06892548 (opens the source filing in a new tab)

  6. Trial

    PHASE2 registered

    Mar 3, 2025

    Non-small Cell Lung Cancer · RECRUITING · sponsor: BioNTech SE · Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

    ClinicalTrials.gov · NCT06841055 (opens the source filing in a new tab)

  7. Trial

    PHASE3 registered

    Feb 3, 2025

    Extensive-stage Small-cell Lung Cancer · RECRUITING · sponsor: BioNTech SE · Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

    ClinicalTrials.gov · NCT06712355 (opens the source filing in a new tab)

  8. Trial

    PHASE1/PHASE2 registered

    Mar 27, 2024

    Pancreatic Cancer · TERMINATED · sponsor: BioNTech SE · Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

    ClinicalTrials.gov · NCT06069778 (opens the source filing in a new tab)

  9. Trial

    PHASE1/PHASE2 registered

    Sep 21, 2023

    Monkeypox · COMPLETED · sponsor: BioNTech SE · A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

    ClinicalTrials.gov · NCT05988203 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources